Matt has been a healthcare-focused venture capital investor since 1980 and began his career as an investment professional with Citicorp Venture Capital. In 1991 he formed Mackowski & Shepler, the predecessor to Telegraph Hill Partners, and over nine years took an active or founding role with eight companies, primarily in medical and life science technologies. Matt has represented THP on the boards of Althea Technologies (acquired by Ajinomoto), Ambion (acquired by Applied Biosystems), Asuragen (acquired by Bio-Techne), Emerging Therapy Solutions, Interface Associates (acquired by NDC), Kinetikos Medical (acquired by Integra), Magstim, MedPricer (acquired by Premier), Teknova (NASDAQ:TKNO), and TrakCel; and is an observer on the board of Nimble Therapeutics. Matt received a BA from Duke University and an MBA from The Wharton School.
